Part 8/Chapter 51/6-min read

Connective-Tissue Arteriopathies and Other Rare Nonatherosclerotic Arterial Disorders

Connective-tissue arteriopathies and other rare nonatherosclerotic disorders treated as phenotype-driven decisions: when natural-history risk exceeds intervention risk in Marfan, Loeys-Dietz, vascular Ehlers-Danlos, and related conditions. The chapter frames prophylactic aortic repair thresholds and the vascular consequences of inherited and rare arterial disease.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·7 sections · 21 references

Listen to this chapter8 min · AI audio edition · two hostsAI narration

Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.

General medical education, not patient-specific advice.

Choose the hosts

Definition and presentation

Inherited connective-tissue arteriopathies present with thoracic aortic aneurysms or dissections at unusually young ages, often accompanied by syndromic features, uncommon arterial territory involvement, or a family history of vascular events . The presentation and natural history depend on the specific syndrome and pathogenic variant:

  • Marfan syndrome (FBN1 variant): Characterized by aortic-root dilation, mitral valve prolapse, and skeletal habitus.
  • Loeys-Dietz syndrome (TGFBR1, TGFBR2, TGFB2, TGFB3 variants): Characterized by aggressive dissection risk at smaller diameters than Marfan syndrome.
  • Vascular Ehlers-Danlos syndrome (vEDS, COL3A1 variant): Characterized by widespread tissue fragility, clinically silent arterial lesions, and unpredictable catastrophic rupture.
  • Aneurysms-osteoarthritis syndrome (SMAD3 variant): Characterized by familial thoracic aortic aneurysm paired with early-onset osteoarthritis .
  • Smooth-muscle dysfunction (ACTA2 variant): The single most common gene in heritable thoracic aortic disease, characterized by premature stroke and coronary artery disease with moyamoya-like cerebrovascular changes.
  • Familial thoracic aortic aneurysm (MYH11 variant): Characterized by a patent ductus arteriosus association.

Genetic diagnosis and phenotyping

Targeted genetic testing is central to evaluation for patients presenting with thoracic aortic aneurysm at a young age or with a positive family history . A confirmed gene-level diagnosis establishes the surgical threshold, the territories requiring imaging, and the dissection risk. Once a pathogenic variant is identified, cascade genetic testing of first-degree relatives identifies asymptomatic carriers for surveillance before a first dissection or rupture .

Variant classification affects phenotypic severity and operative planning. In Marfan syndrome, cysteine-affecting and premature-termination FBN1 variants are associated with more severe aortic phenotypes than missense variants of uncertain significance . Collaboration with medical genetics ensures accurate interpretation as variant classifications evolve.

Diagnosis and surveillance

Surveillance combines local and systemic imaging based on the genotype. In Marfan syndrome, echocardiography monitors aortic-root diameter and mitral valve morphology, while cross-sectional computed tomography angiography (CTA) or magnetic resonance angiography (MRA) maps the entire aorta to detect distal disease . After a new Marfan diagnosis, obtain a baseline echocardiogram, repeat at 6 months to establish the growth rate, then image annually if the root is stable and well below threshold. Move to every 6 months or shorter once the diameter reaches 4.5 cm, approaches the operative threshold, or grows rapidly. Obtain whole-aorta CTA or MRA at baseline and periodically to cover segments echocardiography cannot see. A higher prevalence of unruptured intracranial aneurysms in Marfan syndrome supports one-time intracranial screening, with subsequent rupture-risk decisions following standard intracranial criteria .

In vascular Ehlers-Danlos syndrome, widespread and clinically silent arterial lesions (aneurysms, dissections, fistulae) support baseline and periodic head-to-pelvis arterial imaging .

Medical therapy

Medical therapy slows arterial dilation but does not eliminate event risk or replace the need for surveillance and prophylactic surgery.

In Marfan syndrome, both angiotensin receptor blockers (ARBs) and beta-blockers slow aortic-root growth. Individual-patient-data meta-analysis supports both agents, with combination therapy providing additive benefit in some subgroups when tolerated . Trial evidence supports an ARB class effect across age groups . The pediatric trial framework establishes losartan and atenolol as standard agents for childhood-onset disease .

In vascular Ehlers-Danlos syndrome, celiprolol is used as a medical-risk modifier to reduce arterial event rates, although regional availability varies .

Intervention thresholds and surgical decision-making

The decision to intervene balances the natural history of the specific genetic variant against procedural risk. In connective-tissue arteriopathy, surgical indications follow gene-specific thresholds rather than sporadic aneurysm criteria.

Decision threshold

Operative thresholds and strategies in inherited arteriopathies

  1. Marfan syndrome, low operative risk
    Aortic root >= 5.0 cm
    Elective prophylactic aortic-root surgery
  2. Marfan syndrome, high risk modifiers
    Aortic root 4.5 to 5.0 cm plus rapid growth or family history of dissection
    Elective prophylactic aortic-root surgery
  3. Loeys-Dietz syndrome
    Aortic root or ascending aorta >= 4.5 cm; earlier repair down to ~4.0 cm for high-risk genotypes or features (TGFBR2, severe cutaneous or skeletal phenotype, family history of early dissection). TGFB2 and TGFB3 variants behave less aggressively and may be managed nearer Marfan thresholds
    Prophylactic surgery based on gene severity
  4. Vascular Ehlers-Danlos syndrome, asymptomatic
    Any diameter
    Avoid elective intervention; maintain centralized surveillance
  5. Vascular Ehlers-Danlos syndrome, emergency
    Life- or limb-threatening rupture or ischemia
    Damage-control intervention prioritizing immediate control
Source · ·

The operative pathway requires structured decision-making:

  1. Establish the gene-specific phenotype to define surgical thresholds and arterial territories at risk.
  2. Decide surveillance versus prophylactic repair based on established diameter thresholds, confirmed growth rates, and family history.
  3. For elective repair in Marfan and Loeys-Dietz syndromes, select valve-sparing root replacement in eligible candidates or composite valve-graft replacement based on valve morphology and center experience . Open valve-sparing or composite aortic root replacement is the standard elective operation; endovascular repair (TEVAR) is generally avoided in the native connective-tissue aorta and reserved for selected distal or dissection scenarios or as a bridge to definitive open reconstruction .
  4. In vascular Ehlers-Danlos syndrome, avoid elective open or endovascular reconstruction. Tissue fragility and high complication risk make routine intervention inappropriate.
  5. In life- or limb-threatening emergencies, prioritize the least anatomically ambitious operation that secures immediate hemorrhage or ischemia control, anticipating access complications and suture-line failure .

Special populations

Pregnancy in vascular Ehlers-Danlos syndrome carries a materially increased risk of arterial and uterine rupture. Management requires preconception counseling and tertiary-care coordination among maternal-fetal medicine, anesthesia, and vascular surgery. Routine elective arterial intervention is avoided during pregnancy unless a life-threatening indication emerges .

Pediatric vascular Ehlers-Danlos syndrome requires early diagnosis to facilitate activity modification, sport guidance, and connection to a specialist pathway prior to the first arterial event .

Quality of life is reduced in Marfan syndrome, driven substantially by prior aortic intervention and musculoskeletal involvement. These factors directly affect recovery expectations and surveillance adherence .

In women with Marfan syndrome contemplating pregnancy, prophylactic aortic root or ascending replacement before conception is reasonable at a diameter >= 4.5 cm. Dissection risk rises materially once the aorta exceeds ~4.0 cm, so counsel before pregnancy, maintain strict beta-blockade, and follow with serial echocardiography through pregnancy and the postpartum period .

Areas of controversy

Aortic biomechanical properties, including stiffness and strain, and advanced three-dimensional imaging are under investigation as early markers of Marfan aortic dilation but remain research-stage metrics rather than established surgical triggers . Novel pharmacologic adjuncts, such as resveratrol, lack validated clinical endpoints and are not part of routine therapy outside trial settings . Gene-specific surgical thresholds for Loeys-Dietz syndrome continue to evolve as new genotype-phenotype correlations emerge . In asymptomatic vascular Ehlers-Danlos syndrome, the optimal interval for head-to-pelvis surveillance imaging is not standardized and relies on center-level expertise .

References

  1. 1.
    2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. 2023.
    PubMed-indexed articleClinical practice guideline2022

    2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. 2023. doi:10.1016/j.jtcvs.2023.04.023.

    PubMedDOI
  2. 2.
    Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circulation research. 2011.
    PubMed-indexed article2011

    Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circulation research. 2011. doi:10.1161/circresaha.111.248161.

    PubMedDOI
  3. 3.
    Genetic screening in heritable thoracic aortic disease-rationale, potentials and pitfalls. Indian journal of thoracic and cardiovascular surgery. 2022.
    PubMed-indexed articleReview2022

    Genetic screening in heritable thoracic aortic disease-rationale, potentials and pitfalls. Indian journal of thoracic and cardiovascular surgery. 2022. doi:10.1007/s12055-020-01124-7.

    PubMedDOI
  4. 4.
    Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource's FBN1 variant curation expert panel. Genome medicine. 2024.
    PubMed-indexed article2024

    Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource's FBN1 variant curation expert panel. Genome medicine. 2024. doi:10.1186/s13073-024-01423-3.

    PubMedDOI
  5. 5.
    Clinical and Phenotypic Correlates of Mitral Valve Prolapse in Marfan Syndrome: The Cornell Aortic Aneurysm Registry. Journal of the American Heart Association. 2025.
    PubMed-indexed articleRegistry / cohort2025

    Clinical and Phenotypic Correlates of Mitral Valve Prolapse in Marfan Syndrome: The Cornell Aortic Aneurysm Registry. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.040947.

    PubMedDOI
  6. 6.
    Prevalence of unruptured intracranial aneurysms in patients with Marfan syndrome: A cross-sectional study and meta-analysis. European stroke journal. 2023.
    PubMed-indexed articleMeta-analysis / systematic review2023

    Prevalence of unruptured intracranial aneurysms in patients with Marfan syndrome: A cross-sectional study and meta-analysis. European stroke journal. 2023. doi:10.1177/23969873221149848.

    PubMedDOI
  7. 7.
    Assessment of arterial damage in vascular Ehlers-Danlos syndrome: A retrospective multicentric cohort. Frontiers in cardiovascular medicine. 2022.
    PubMed-indexed articleRegistry / cohort2022

    Assessment of arterial damage in vascular Ehlers-Danlos syndrome: A retrospective multicentric cohort. Frontiers in cardiovascular medicine. 2022. doi:10.3389/fcvm.2022.953894.

    PubMedDOI
  8. 8.
    Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet (London, England). 2022.
    PubMed-indexed articleMeta-analysis / systematic review2022

    Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet (London, England). 2022. doi:10.1016/s0140-6736(22)01534-3.

    PubMedDOI
  9. 9.
    Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet (London, England). 2019.
    PubMed-indexed articleRandomized controlled trial2019

    Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet (London, England). 2019. doi:10.1016/s0140-6736(19)32518-8.

    PubMedDOI
  10. 10.
    Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. European heart journal. 2020.
    PubMed-indexed articleRandomized controlled trial2020

    Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. European heart journal. 2020. doi:10.1093/eurheartj/ehaa377.

    PubMedDOI
  11. 11.
    Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. American heart journal. 2007.
    PubMed-indexed article2007

    Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. American heart journal. 2007. doi:10.1016/j.ahj.2007.06.024.

    PubMedDOI
  12. 12.
    Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. American heart journal. 2013.
    PubMed-indexed article2013

    Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. American heart journal. 2013. doi:10.1016/j.ahj.2013.02.019.

    PubMedDOI
  13. 13.
    Vascular Ehlers-Danlos Syndrome: A Comprehensive Natural History Study in a Dutch National Cohort of 142 Patients. Circulation. Genomic and precision medicine. 2024.
    PubMed-indexed articleRegistry / cohort2024

    Vascular Ehlers-Danlos Syndrome: A Comprehensive Natural History Study in a Dutch National Cohort of 142 Patients. Circulation. Genomic and precision medicine. 2024. doi:10.1161/circgen.122.003978.

    PubMedDOI
  14. 14.
    Diagnosis and management of vascular Ehlers-Danlos syndrome: Experience of the UK national diagnostic service, Sheffield. European journal of human genetics: EJHG. 2023.
    PubMed-indexed articleRegistry / cohort2023

    Diagnosis and management of vascular Ehlers-Danlos syndrome: Experience of the UK national diagnostic service, Sheffield. European journal of human genetics: EJHG. 2023. doi:10.1038/s41431-023-01343-7.

    PubMedDOI
  15. 15.
    Association Between Genetic Diagnosis and Clinical Outcomes in Patients With Heritable Thoracic Aortic Disease. Journal of the American Heart Association. 2023.
    PubMed-indexed articleRegistry / cohort2023

    Association Between Genetic Diagnosis and Clinical Outcomes in Patients With Heritable Thoracic Aortic Disease. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028625.

    PubMedDOI
  16. 16.
    Aortic root surgery in Marfan syndrome. Indian journal of thoracic and cardiovascular surgery. 2019.
    PubMed-indexed article2019

    Aortic root surgery in Marfan syndrome. Indian journal of thoracic and cardiovascular surgery. 2019. doi:10.1007/s12055-018-0761-9.

    PubMedDOI
  17. 17.
    Pregnancy and Delivery Outcomes in Vascular Ehlers-Danlos Syndrome: A Retrospective Multicentre Cohort Study. BJOG: an international journal of obstetrics and gynaecology. 2026.
    PubMed-indexed articleRegistry / cohort2026

    Pregnancy and Delivery Outcomes in Vascular Ehlers-Danlos Syndrome: A Retrospective Multicentre Cohort Study. BJOG: an international journal of obstetrics and gynaecology. 2026. doi:10.1111/1471-0528.18142.

    PubMedDOI
  18. 18.
    Vascular Ehlers-Danlos syndrome in children: evaluating the importance of diagnosis and follow-up during childhood. European journal of human genetics: EJHG. 2025.
    PubMed-indexed articleRegistry / cohort2025

    Vascular Ehlers-Danlos syndrome in children: evaluating the importance of diagnosis and follow-up during childhood. European journal of human genetics: EJHG. 2025. doi:10.1038/s41431-024-01773-x.

    PubMedDOI
  19. 19.
    Marfan Syndrome and Quality of Life in the GenTAC Registry. Journal of the American College of Cardiology. 2017.
    PubMed-indexed articleRegistry / cohort2017

    Marfan Syndrome and Quality of Life in the GenTAC Registry. Journal of the American College of Cardiology. 2017. doi:10.1016/j.jacc.2017.04.026.

    PubMedDOI
  20. 20.
    Are aortic biomechanical properties early markers of dilatation in patients with Marfan syndrome? A systematic review and meta-analysis. Biomechanics and modeling in mechanobiology. 2024.
    PubMed-indexed articleMeta-analysis / systematic review2024

    Are aortic biomechanical properties early markers of dilatation in patients with Marfan syndrome? A systematic review and meta-analysis. Biomechanics and modeling in mechanobiology. 2024. doi:10.1007/s10237-024-01881-z.

    PubMedDOI
  21. 21.
    Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial. Heart (British Cardiac Society). 2024.
    PubMed-indexed article2024

    Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial. Heart (British Cardiac Society). 2024. doi:10.1136/heartjnl-2024-324343.

    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions